PT1005328E - Composicao compreendendo particulas de budesonido cristalinas finamente divididas - Google Patents

Composicao compreendendo particulas de budesonido cristalinas finamente divididas

Info

Publication number
PT1005328E
PT1005328E PT98924697T PT98924697T PT1005328E PT 1005328 E PT1005328 E PT 1005328E PT 98924697 T PT98924697 T PT 98924697T PT 98924697 T PT98924697 T PT 98924697T PT 1005328 E PT1005328 E PT 1005328E
Authority
PT
Portugal
Prior art keywords
budsonido
crystallines
particles
finally divided
composition understanding
Prior art date
Application number
PT98924697T
Other languages
English (en)
Inventor
Mikael Bisrat
Saeed Moshashaee
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1005328E publication Critical patent/PT1005328E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT98924697T 1997-05-23 1998-05-15 Composicao compreendendo particulas de budesonido cristalinas finamente divididas PT1005328E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9701956A SE9701956D0 (sv) 1997-05-23 1997-05-23 New composition of matter

Publications (1)

Publication Number Publication Date
PT1005328E true PT1005328E (pt) 2003-11-28

Family

ID=20407079

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98924697T PT1005328E (pt) 1997-05-23 1998-05-15 Composicao compreendendo particulas de budesonido cristalinas finamente divididas

Country Status (28)

Country Link
US (2) US6346523B1 (pt)
EP (1) EP1005328B1 (pt)
JP (1) JP2001525850A (pt)
KR (1) KR100514971B1 (pt)
CN (1) CN1146406C (pt)
AR (1) AR015820A1 (pt)
AT (1) ATE246492T1 (pt)
AU (1) AU734763B2 (pt)
BR (1) BR9808812A (pt)
CA (1) CA2290538C (pt)
DE (1) DE69816997T2 (pt)
DK (1) DK1005328T3 (pt)
EE (1) EE03850B1 (pt)
ES (1) ES2205496T3 (pt)
HU (1) HUP0002212A3 (pt)
ID (1) ID24332A (pt)
IL (1) IL133098A (pt)
IS (1) IS5254A (pt)
NO (1) NO995540L (pt)
NZ (1) NZ500852A (pt)
PL (1) PL336902A1 (pt)
PT (1) PT1005328E (pt)
SE (1) SE9701956D0 (pt)
SK (1) SK158799A3 (pt)
TR (1) TR199902880T2 (pt)
TW (1) TW518236B (pt)
WO (1) WO1998052544A1 (pt)
ZA (1) ZA984127B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213638C (en) * 1995-02-24 2004-05-04 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
CN1192810C (zh) * 2000-03-03 2005-03-16 贝林格尔·英格海姆药物公司 通过反复的溶剂膨胀-收缩处理物料
EP1354581A4 (en) * 2000-12-26 2007-07-04 Takeda Pharmaceutical POROUS SUBSTANCE AND METHOD FOR THE PRODUCTION THEREOF
GB0106403D0 (en) * 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
EP1423175B1 (en) 2001-08-08 2013-10-02 Brown University Research Foundation Methods for micronization of hydrophobic drugs
WO2003030871A1 (en) * 2001-10-10 2003-04-17 Boehringer Ingelheim Pharmaceuticals, Inc. Powder processing with pressurized gaseous fluids
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP2007501683A (ja) 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド γ線照射によるナノ粒子活性物質分散体の滅菌法
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
EP1730751B1 (en) * 2004-03-12 2009-10-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A magnetoresistive medium
EP1871344A4 (en) * 2005-03-18 2012-05-02 Nanomaterials Tech Pte Ltd INHIBITABLE MEDICINAL PRODUCT
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc METHOD FOR FORMING PARTICLES
EP1782839A1 (en) 2005-11-03 2007-05-09 Genetic S.p.A. Sterilization process of Glucocorticosteroid by supercritical CO2
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
CA2642577A1 (en) * 2006-02-15 2007-08-23 Tika Lakemedel Ab Methods of manufacturing corticosteroid solutions
DK2425820T3 (en) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
US20100294986A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Supercritical fluid facilitated particle formation in microfluidic systems
US20100298602A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Systems and methods for microfluidic crystallization
CA2812262A1 (en) * 2010-09-22 2012-03-29 Map Pharmaceuticals, Inc. Aerosol composition for administering drugs
CN102975731B (zh) * 2012-04-24 2015-08-12 南车南京浦镇车辆有限公司 轨道车辆司机室骨架与车体的安装结构
WO2021219230A1 (en) 2020-04-30 2021-11-04 Paolo Fiorina Antiviral treatment
KR102567655B1 (ko) 2020-11-13 2023-08-17 주식회사 비츠로이엠 진공커패시터 및 진공커패시터 제조 방법
KR20230072023A (ko) 2021-11-17 2023-05-24 주식회사 비츠로이엠 가변형 진공 커패시터의 나선형 전극 위치 결정구조
KR20230072022A (ko) 2021-11-17 2023-05-24 주식회사 비츠로이엠 가변형 진공 커패시터

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
EP0437451B1 (en) 1988-10-05 1993-06-09 The Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
IE67187B1 (en) 1990-06-15 1996-03-06 Merck & Co Inc A crystallization method to improve crystal structure and size
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
JP3342484B2 (ja) * 1991-12-18 2002-11-11 アストラ・アクチエボラーグ 新規な配合
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles

Also Published As

Publication number Publication date
TR199902880T2 (xx) 2000-02-21
NO995540D0 (no) 1999-11-12
US6468994B2 (en) 2002-10-22
ZA984127B (en) 1998-11-23
CA2290538C (en) 2007-01-02
NZ500852A (en) 2001-07-27
ID24332A (id) 2000-07-13
HUP0002212A3 (en) 2001-04-28
EP1005328A1 (en) 2000-06-07
IL133098A (en) 2005-03-20
US20020037257A1 (en) 2002-03-28
IS5254A (is) 1999-11-18
EP1005328B1 (en) 2003-08-06
WO1998052544A1 (en) 1998-11-26
SE9701956D0 (sv) 1997-05-23
HUP0002212A2 (hu) 2000-12-28
CN1146406C (zh) 2004-04-21
CA2290538A1 (en) 1998-11-26
IL133098A0 (en) 2001-03-19
AU7680098A (en) 1998-12-11
DE69816997D1 (de) 2003-09-11
ATE246492T1 (de) 2003-08-15
SK158799A3 (en) 2000-05-16
DK1005328T3 (da) 2003-11-17
KR100514971B1 (ko) 2005-09-15
TW518236B (en) 2003-01-21
ES2205496T3 (es) 2004-05-01
DE69816997T2 (de) 2004-07-22
NO995540L (no) 1999-11-12
BR9808812A (pt) 2000-07-18
PL336902A1 (en) 2000-07-17
AU734763B2 (en) 2001-06-21
US6346523B1 (en) 2002-02-12
JP2001525850A (ja) 2001-12-11
AR015820A1 (es) 2001-05-30
EE03850B1 (et) 2002-10-15
KR20010012821A (ko) 2001-02-26
CN1257424A (zh) 2000-06-21
EE9900533A (et) 2000-06-15

Similar Documents

Publication Publication Date Title
PT1005328E (pt) Composicao compreendendo particulas de budesonido cristalinas finamente divididas
BR9509200A (pt) Composição de matéria
BR9403946A (pt) Composição de matéria
PT1066027E (pt) Composicao farmaceutica de topiramato
NO20004345D0 (no) Farmasøytisk sammensetning
PT907364E (pt) Composicao farmaceutica de libertacao sustida
ID25508A (id) Komposisi dematologis
BR9607058A (pt) Composição
BR9606809A (pt) Composição inseticidamente ativa
ID26820A (id) Aglomerat partikel
PT728814E (pt) Composicao betuminosa
ID23250A (id) Komposisi paroksetin
ID21906A (id) Komposisi adesif
BR9612279A (pt) Composição eletrodepositável
BR9609903A (pt) ComposiçÃo inseticidamente ativa
ID29294A (id) Komposisi farmasi
LV11727A (lv) Farmaceitiska kompozicija
FI973229A (fi) Uusi farmaseuttinen koostumus
MA26531A1 (fr) Composition pharmaceutique
PT1222921E (pt) Composicoes farmaceuticas de tizoxanida e nitazoxanida
DE69616374T2 (de) Germizide zusammensetzung
ID25857A (id) Komposisi farmasi
ID16838A (id) Komposisi dekafluoropentana
FI973280A (fi) Farmaseuttinen koostumus
DE69623493D1 (de) Enzymatische zusammensetzung